Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema. The company also engages in the development of therapies in various areas, such as gene therapy for inherited retinal disorders, neovascular age-related macular degeneration, and other ocular diseases. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLSD
Previous Symbol
CUSIPN/A
Phone678-270-3631
Debt
Debt-to-Equity Ratio0.15
Current Ratio7.94
Quick Ratio7.94
Price-To-Earnings
Trailing P/E Ratio-2.28
Forward P/E Ratio-2.10
P/E GrowthN/A
Sales & Book Value
Annual Sales$340,000.00
Price / Sales501.02
Cash FlowN/A
Price / CashN/A
Book Value$0.84 per share
Price / Book6.33
Profitability
EPS (Most Recent Fiscal Year)($2.33)
Net Income$-58,970,000.00
Net MarginsN/A
Return on Equity-136.82%
Return on Assets-100.25%
Miscellaneous
Employees34
Outstanding Shares32,020,000
Market Cap$175.49 million
OptionableOptionable
Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions
What is Clearside Biomedical's stock symbol?
Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."
How were Clearside Biomedical's earnings last quarter?
Clearside Biomedical Inc (NASDAQ:CLSD) released its quarterly earnings results on Wednesday, August, 8th. The company reported ($0.65) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.58) by $0.07. View Clearside Biomedical's Earnings History.
When is Clearside Biomedical's next earnings date?
What price target have analysts set for CLSD?
7 analysts have issued 12 month target prices for Clearside Biomedical's stock. Their forecasts range from $18.00 to $29.00. On average, they expect Clearside Biomedical's share price to reach $22.40 in the next twelve months. This suggests a possible upside of 321.1% from the stock's current price. View Analyst Price Targets for Clearside Biomedical.
What is the consensus analysts' recommendation for Clearside Biomedical?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clearside Biomedical.
Who are some of Clearside Biomedical's key competitors?
Some companies that are related to Clearside Biomedical include Epizyme (EPZM), CytomX Therapeutics (CTMX), Dynavax Technologies (DVAX), Insys Therapeutics (INSY), ANI Pharmaceuticals (ANIP), NuCana (NCNA), Vectura Group (VEGPF), AC Immune (ACIU), CymaBay Therapeutics (CBAY), GlycoMimetics (GLYC), Obseva (OBSV), Assembly Biosciences (ASMB), Dova Pharmaceuticals (DOVA), Urogen Pharma (URGN) and ChemoCentryx (CCXI).
Who are Clearside Biomedical's key executives?
Clearside Biomedical's management team includes the folowing people:
- Mr. Daniel H. White, Founder, Pres, CEO & Director (Age 51)
- Mr. Charles A. Deignan, CFO & Sec. (Age 54)
- Dr. Glenn Noronha, Chief Scientific Officer (Age 53)
- Mr. Leslie B. Zacks, Gen. Counsel & Chief Compliance Officer (Age 49)
- Mr. Brion S. Raymond, Chief Commercial Officer (Age 48)
When did Clearside Biomedical IPO?
(CLSD) raised $50 million in an initial public offering (IPO) on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.
How do I buy shares of Clearside Biomedical?
Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clearside Biomedical's stock price today?
One share of CLSD stock can currently be purchased for approximately $5.32.
How big of a company is Clearside Biomedical?
Clearside Biomedical has a market capitalization of $175.49 million and generates $340,000.00 in revenue each year. The company earns $-58,970,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Clearside Biomedical employs 34 workers across the globe.
What is Clearside Biomedical's official website?
How can I contact Clearside Biomedical?
Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]
MarketBeat Community Rating for Clearside Biomedical (NASDAQ CLSD)
MarketBeat's community ratings are surveys of what our community members think about Clearside Biomedical and other stocks. Vote "Outperform" if you believe CLSD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSD will underperform the S&P 500 over the long term. You may vote once every thirty days.
